Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)
China · Delayed Price · Currency is CNY 19.68
-0.44 (-2.19%)
Sep 11, 2026, 3:04 PM CST
SHE:300204 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 187.48 | 220.19 | 324.75 | 364.04 | 548.99 | 584.28 |
Other Revenue | 0.05 | 0.04 | 0.07 | 0.13 | - | 0.01 |
| 187.53 | 220.23 | 324.82 | 364.18 | 548.99 | 584.29 | |
Revenue Growth | -30.03% | -32.20% | -10.81% | -33.66% | -6.04% | 37.41% |
Cost of Revenue | 47.38 | 50.29 | 62.27 | 74.6 | 101.77 | 116.43 |
Gross Profit | 140.15 | 169.95 | 262.55 | 289.57 | 447.22 | 467.86 |
Selling, General & Admin | 152.54 | 164.49 | 195.91 | 248.23 | 310.77 | 336.76 |
Research & Development | 68.46 | 84.94 | 107.11 | 412.26 | 362.81 | 362.51 |
Other Operating Expenses | 5.67 | 3.75 | 4.08 | 4.43 | 6.72 | 7.82 |
Operating Expenses | 226.57 | 253.13 | 306.86 | 663.44 | 681.08 | 707.37 |
Operating Income | -86.42 | -83.18 | -44.31 | -373.86 | -233.87 | -239.51 |
Interest Expense | -15.36 | -8.49 | -0.64 | -1.17 | -0.36 | -0.65 |
Interest & Investment Income | 1.75 | 0.97 | 0.63 | 2.65 | 7.32 | 22.19 |
Currency Exchange Gain (Loss) | -0.68 | -0.26 | 0.24 | 0 | 0 | -0 |
Other Non Operating Income (Expenses) | 0.13 | -0.15 | -0.21 | 0.02 | -0.24 | 1.46 |
EBT Excluding Unusual Items | -100.58 | -91.11 | -44.3 | -372.36 | -227.14 | -216.51 |
Impairment of Goodwill | - | - | - | - | -2.42 | - |
Gain (Loss) on Sale of Investments | 0.01 | - | - | -0 | -1.46 | 0.21 |
Gain (Loss) on Sale of Assets | -0.33 | 0.64 | 0.2 | 0.3 | -0.04 | - |
Asset Writedown | -1.83 | -1.83 | - | -2.34 | -21.71 | -0.09 |
Other Unusual Items | 4.71 | 3.97 | 9.79 | 7.96 | 9.69 | 3.42 |
Pretax Income | -98.02 | -88.32 | -34.32 | -366.45 | -243.07 | -212.96 |
Income Tax Expense | -0.29 | -0.22 | 113.42 | 32.44 | -46.06 | -75.56 |
Earnings From Continuing Operations | -97.73 | -88.11 | -147.73 | -398.89 | -197.01 | -137.4 |
Minority Interest in Earnings | 7.83 | 10.34 | 2.89 | - | - | - |
Net Income | -89.9 | -77.76 | -144.84 | -398.89 | -197.01 | -137.4 |
Net Income to Common | -89.9 | -77.76 | -144.84 | -398.89 | -197.01 | -137.4 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 469 | 486 | 483 | 475 | 481 | 474 |
Shares Outstanding (Diluted) | 469 | 486 | 483 | 475 | 481 | 474 |
Shares Change | -15.87% | 0.66% | 1.67% | -1.17% | 1.42% | -0.27% |
EPS (Basic) | -0.19 | -0.16 | -0.30 | -0.84 | -0.41 | -0.29 |
EPS (Diluted) | -0.19 | -0.16 | -0.30 | -0.84 | -0.41 | -0.29 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -193.5 | -202.31 | -87.21 | -260.47 | -232.12 | -218.31 |
Free Cash Flow Per Share | -0.41 | -0.42 | -0.18 | -0.55 | -0.48 | -0.46 |
Gross Margin | 74.73% | 77.17% | 80.83% | 79.52% | 81.46% | 80.07% |
Operating Margin | -46.08% | -37.77% | -13.64% | -102.66% | -42.60% | -40.99% |
Profit Margin | -47.94% | -35.31% | -44.59% | -109.53% | -35.89% | -23.52% |
Free Cash Flow Margin | -103.18% | -91.86% | -26.85% | -71.52% | -42.28% | -37.36% |
EBITDA | -61.99 | -59.62 | -21.58 | -342.43 | -202.38 | -205.42 |
EBITDA Margin | -33.05% | -27.07% | -6.64% | -94.03% | -36.86% | -35.16% |
D&A For EBITDA | 24.43 | 23.57 | 22.73 | 31.44 | 31.48 | 34.09 |
EBIT | -86.42 | -83.18 | -44.31 | -373.86 | -233.87 | -239.51 |
EBIT Margin | -46.08% | -37.77% | -13.64% | -102.66% | -42.60% | -40.99% |
Revenue as Reported | 187.53 | 220.23 | 324.82 | 364.18 | 548.99 | 584.29 |